Adicet Bio Total Assets Growth & History (ACET)
Adicet Bio's total assets was $192.4M for fiscal 2025.
View full Adicet Bio company overviewAdicet Bio annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $192.4M | −$27.9M | −12.65% |
| 2024 | 2024-12-31 | $220.2M | $12.9M | +6.23% |
| 2023 | 2023-12-31 | $207.3M | −$123.4M | −37.31% |
| 2022 | 2022-12-31 | $330.7M | −$8.2M | −2.43% |
| 2021 | 2021-12-31 | $338.9M | $185.1M | +120.33% |
| 2020 | 2020-12-31 | $153.8M | $72.2M | +88.55% |
| 2019 | 2019-12-31 | $81.6M | −$28.4M | −25.79% |
| 2018 | 2018-12-31 | $109.9M | $54.7M | +99.19% |
| 2017 | 2017-12-31 | $55.2M | — | — |
Adicet Bio quarterly total assets
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $148.2M | −$14.8M | −9.08% |
| Q1 2026 | 2026-03-31 | $169.4M | −$21.9M | −11.44% |
| Q4 2025 | 2025-12-31 | $192.4M | −$27.9M | −12.65% |
| Q3 2025 | 2025-09-30 | $140.5M | −$105.5M | −42.89% |
| Q2 2025 | 2025-06-30 | $163.0M | −$105.9M | −39.38% |
| Q1 2025 | 2025-03-31 | $191.3M | −$101.8M | −34.74% |
| Q4 2024 | 2024-12-31 | $220.2M | $12.9M | +6.23% |
| Q3 2024 | 2024-09-30 | $246.0M | $12.7M | +5.45% |
| Q2 2024 | 2024-06-30 | $268.8M | −$8.8M | −3.17% |
| Q1 2024 | 2024-03-31 | $293.1M | −$11.9M | −3.90% |
| Q4 2023 | 2023-12-31 | $207.3M | −$123.4M | −37.31% |
| Q3 2023 | 2023-09-30 | $233.3M | −$121.0M | −34.16% |
| Q2 2023 | 2023-06-30 | $277.6M | −$52.3M | −15.84% |
| Q1 2023 | 2023-03-31 | $305.0M | −$35.5M | −10.42% |
| Q4 2022 | 2022-12-31 | $330.7M | −$8.2M | −2.43% |
| Q3 2022 | 2022-09-30 | $354.3M | $97.1M | +37.76% |
| Q2 2022 | 2022-06-30 | $329.9M | $61.1M | +22.74% |
| Q1 2022 | 2022-03-31 | $340.5M | $58.4M | +20.70% |
| Q4 2021 | 2021-12-31 | $338.9M | $185.1M | +120.33% |
| Q3 2021 | 2021-09-30 | $257.2M | $106.8M | +71.01% |
| Q2 2021 | 2021-06-30 | $268.8M | $194.4M | +261.54% |
| Q1 2021 | 2021-03-31 | $282.1M | $203.9M | +260.68% |
| Q4 2020 | 2020-12-31 | $153.8M | $72.2M | +88.55% |
| Q3 2020 | 2020-09-30 | $150.4M | $28.4M | +23.31% |
| Q2 2020 | 2020-06-30 | $74.3M | −$62.3M | −45.60% |
| Q1 2020 | 2020-03-31 | $78.2M | −$66.9M | −46.09% |
| Q4 2019 | 2019-12-31 | $81.6M | −$28.4M | −25.79% |
| Q3 2019 | 2019-09-30 | $122.0M | $4.5M | +3.86% |
| Q2 2019 | 2019-06-30 | $136.7M | $7.9M | +6.12% |
| Q1 2019 | 2019-03-31 | $145.1M | $7.8M | +5.71% |
| Q4 2018 | 2018-12-31 | $109.9M | $54.7M | +99.19% |
| Q3 2018 | 2018-09-30 | $117.4M | — | — |
| Q2 2018 | 2018-06-30 | $128.8M | — | — |
| Q1 2018 | 2018-03-31 | $137.2M | — | — |
| Q4 2017 | 2017-12-31 | $55.2M | — | — |
Adicet Bio total assets trends
Over the last five fiscal years, Adicet Bio's total assets increased from $153.8M to $192.4M, a change of $38.5M. The latest reported quarter, Q2 2026, shows $148.2M.
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Adicet Bio source filings ↗